Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
The ESMO Congress 2022 presented the very latest advances in the treatment of cancer and offered an excellent educational programme, with opportunities for an exchange of ideas among delegates through an enhanced onsite and virtual experience.
Let's share, debate and celebrate all the new developments that we can bring to our practice.
-
Solange Peters, Lausanne, Switzerland
ESMO President 2020 - 2022
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
